TITLE:
Efficacy and Safety of Seroquel Plus Mood Stabilizer in the Maintenance of Bipolar I Disorder

CONDITION:
Bipolar Disorder

INTERVENTION:
Seroquel, quetiapine fumarate (atypical antipsychotic)

SUMMARY:

      The purpose of this study is to determine whether quetiapine when used as adjunct to lithium
      or divalproex is safe and effective in the maintenance treatment of adult patients with
      Bipolar I Disorder. The study consists of enrollment and 2 phases, the Open-label treatment
      Phase and the Randomized treatment Phase.

      PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation
      was changed to XR after consultation with FDA.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

        Open-Label

          -  A diagnosis of Bipolar I Disorder, Most recent episode Manic (296.4x), or Bipolar I
             Disorder, Most Recent Episode Depressed (296.5x), or Bipolar I Disorder, Most recent
             Episode Mixed (296.6x), with or without psychotic features, as defined by Diagnostic
             and Statistical Manual of Mental Disorders - Fourth Edition (DSM-IV)

          -  At least 1 manic, depressed, or mixed episode in the 2 years prior to the index
             episode.

          -  Able to understand and comply with the requirements of the study.

        Exclusion Criteria:

        Open-Label

          -  Diagnosis of an anxiety disorder as defined by DSM-IV, which was treated with
             medication within the past year.

          -  Known intolerance or lack of response to quetiapine fumarate or to the assigned mood
             stabilizer, as judged by the investigator.

          -  Previously randomized into this study or D1447C00126
      
